TG Therapeutics market cap TGTX
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Nov 2, 2026
- $9.2B
- Highest close in our data
- $9.4B
- Oct 2026
TG Therapeutics is worth $9.2B at the close on Nov 2, 2026, at $59.95 a share.
That is up 79% over the last year and up 81% over five years.
Its highest close in our data was $9.4B in Oct 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $9.2B | $4.5B | $9.4B | +88% |
| 2025 | $4.9B | $4.2B | $6.8B | −4% |
| 2024 | $5.1B | $2B | $5.5B | +96% |
| 2023 | $2.6B | $1B | $5B | +50% |
| 2022 | $1.7B | $583.5M | $2.5B | −37% |
| 2021 | $2.7B | $2.2B | $7.1B | −60% |
| 2020 | $6.8B | $835.8M | $7.1B | +531% |
| 2019 | $1.1B | $333.2M | $1.1B | +228% |
| 2018 | $329.9M | $287.7M | $1.2B | −43% |
| 2017 | $579.3M | $229.9M | $924.8M | +128% |
| 2016 | $254.5M | $254.5M | $553.4M | −59% |
| 2015 | $626.6M | $564.6M | $945.8M | −12% |
| 2014 | $711.3M | $143M | $802.3M | +459% |
| 2013 | $127.3M | $92.5M | $209.6M | +45% |
| 2012 | $87.7M | $8.4M | $179M | +949% |
| 2011 | $8.4M | $8.4M | $25M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest TG Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| TGTXTG Therapeutics | $9.2B |
| PTGXProtagonist Therapeutics | $9B |
| CORTCorcept Therapeutics | $8.7B |
| BMRNBiomarin Pharmaceutical | $11.1B |
| ALKSAlkermes plc. | $7.5B |
| KNSAKiniksa Pharmaceuticals International | $7.1B |
| AMRXAmneal Pharmaceuticals | $6.5B |
| LGNDLigand Pharmaceuticals | $6.1B |
| JAZZJazz Pharmaceuticals | $13.9B |
| INDVIndivior Pharmaceuticals | $4.3B |
| ARQTArcutis Biotherapeutics | $3.9B |
| Peer median | $7.3B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on TG Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.